Update in systemic and targeted therapies in gastrointestinal oncology

Keyphrases

• Targeted Therapy 100%
• Systemic Therapy 100%
• Nivolumab 100%
• Gastrointestinal Oncology 100%
• Clinical Trials 66%
• Penn State 33%
• Targeted Therapeutics 33%
• New Treatment Options 33%
• Medical Center 33%
• Surgical Intervention 33%
• 5-fluorouracil (5-FU) 33%
• Cetuximab 33%
• Docetaxel 33%
• Cisplatin 33%
• Milton 33%
• Intervention Therapy 33%
• Radiation Therapy 33%
• Bevacizumab 33%
• Digestive System 33%
• Clinical Efficacy 33%
• Standard of Care 33%
• Collaborative Care 33%
• Irinotecan 33%
• PEGylated 33%
• Preoperative Chemotherapy 33%
• Pancreatic Carcinoma 33%
• New Standards 33%
• Malignant Disease 33%
• Systemic Treatment 33%
• Gemcitabine 33%
• Subspecialty 33%
• Capecitabine 33%
• Vemurafenib 33%
• Ipilimumab 33%
• FOLFOX 33%
• Gastrointestinal Cancer 33%
• Colorectal Carcinoma 33%
• Hyaluronidase 33%
• Oxaliplatin 33%
• Leucovorin 33%
• Pembrolizumab 33%
• Advanced Biliary Tract Cancer 33%
• Biliary Tract Carcinoma 33%
• Nab-paclitaxel 33%
• Gastroesophageal Carcinoma 33%
• Ramucirumab 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Nivolumab 100%
• Clinical Trial 66%
• Bile Duct Carcinoma 66%
• Capecitabine 66%
• Chemotherapy 33%
• Paclitaxel 33%
• Fluorouracil 33%
• Cetuximab 33%
• Gemcitabine 33%
• Cisplatin 33%
• Docetaxel 33%
• Immunotherapy 33%
• Bevacizumab 33%
• Carcinoma 33%
• Irinotecan 33%
• Health Status 33%
• Pancreas Carcinoma 33%
• Systemic Treatment 33%
• Ipilimumab 33%
• Hypochlorite Sodium 33%
• Colorectal Carcinoma 33%
• Digestive System Cancer 33%
• Vemurafenib 33%
• Pembrolizumab 33%
• Oxaliplatin 33%
• Diseases 33%
• Folinic Acid 33%
• Asparaginase 33%
• Ramucirumab 33%

Medicine and Dentistry

• CAPOX 33%
• Trifluridine 33%
• Lenvatinib 33%
• Ramucirumab 33%
• Asparaginase 33%
• Napabucasin 33%
• Tipiracil 33%